American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
about
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.Use of aromatase inhibitors in practice of gynecologyConjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue.American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused updateAIs: implications for fractures in perimenopausal women with breast cancer.Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.Sequencing of hormonal therapy in breast cancer.Aromatase inhibitors in breast cancer: an update.Aromatase inhibitors for the treatment of infertility.Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study.First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?Role of aromatase inhibitors in breast cancer.MGMT inhibition restores ERα functional sensitivity to antiestrogen therapyEffectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.Emerging drugs in endometriosis.Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligandsMathematical models of breast and ovarian cancers.Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.Male breast cancer: thirteen years experience of a single center.Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman.Endocrine therapy for the treatment of postmenopausal women with breast cancer.Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age.Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.Effectiveness of the antagonist/letrozole protocol for treating poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis.Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.Mammography Findings of Male Breast Diseases.Androgen receptors are frequently expressed in mammary and extramammary Paget's disease.A comparison among different methods of letrozole combined with gonadotropin in an antagonist protocol and high-dose gonadotropin ovarian stimulation antagonist protocol in poor ovarian responders undergoing in vitro fertilization.Salinomycin overcomes acquired tamoxifen resistance through AIB1 and inhibits cancer cell invasion in endocrine resistant breast cancer.David Kupfer and the metabolism connection: on aromatase inhibitors and tamoxifen.Comparison of estradiol and progesterone priming/antagonist/letrozole and microdose flare-up protocols for poor responders undergoing intracytoplasmic sperm injection.Acute but not sustained aromatase inhibition displays antidepressant properties.
P2860
Q24816913-FF4A98C7-4D90-4222-87F6-E6C5DED76317Q27001218-A5B70042-C8FE-4A74-8DA3-EA88A42EA1ACQ33354773-18BED137-D268-4AF3-9B14-D00B6DC90873Q33631047-2214CA58-867E-4B18-95C8-47466165DB07Q34023239-69ED87CB-274B-4674-B9DD-FA6F682A93F8Q34421634-A0E2BDA7-48FC-4C38-B2ED-9D35D56D80E2Q34526604-37EE4175-73DA-4476-8176-243032318B20Q34680563-B9C1D1E2-4D1C-45FB-A520-6FE3EBDC2B38Q34975951-149CB4C8-A56D-4C60-A9C0-39454DF21B03Q35039491-AB0A1E9A-B03F-4E7C-98D2-EFAFCACD02ACQ35073337-58A5BB3B-E5EA-4569-A814-A8CB5AD39C14Q35117738-28A3C1CB-29D7-4054-AEE2-9CBB8B881534Q35203256-2A75FEDF-2751-4EED-8699-E481A946EFEBQ35622444-1D36BBCC-AE7C-4A66-8C02-C09D775775CBQ35692392-CB0D3864-1B70-441A-867C-385E9D63B299Q36085346-BDC34DAE-B7A1-489C-AE65-0D3243A0729BQ36229436-839AAFBD-7380-44D0-B998-6C29C97BBAF1Q36283445-E39DAF55-4CBE-4291-9BC6-3F85AAD530A0Q36530770-6299C4C2-E65C-492C-8607-0E0CB8254347Q36580603-F2CC2D65-BE21-4326-AF78-025E79B0BEC0Q36703918-DC011CF2-18F0-440A-944D-D3DBFB415A6FQ36860892-9806405B-B9C1-4E24-A175-0986863BE8FFQ36983310-B6892103-1CD8-4708-A4E1-407D05B3B558Q37014152-2783ADDE-6FF4-4200-8959-D32922C2DB92Q37074119-E5D92991-EFEB-4303-8EF5-4E119B998F32Q37097549-C4767895-55C2-4496-BCF4-4F4BD6E89299Q37343142-A9870CCC-22B3-4B00-BAE3-9BD7DF8DF11EQ37385376-EED9EC0D-2210-44FC-A856-D5FD820A8F3DQ37845834-35CFB7DF-7223-417E-BD14-ED70DEC6CAE2Q37873372-FC1443B4-52AE-4FDB-8D2F-A669DA9A33DEQ38181172-1BAAC0E0-1517-42DE-BBCE-747B4CF79D0DQ39667297-B6134EFF-CE76-449F-814D-EED9C92DAE59Q40516906-D668C4E5-F0C7-48D7-AF0A-F2176A596F18Q42316324-23F5F4C3-427C-464C-B2BC-ACAB6F05937EQ46513913-3458F0FF-47BD-4D51-8789-E32F2B2DDE92Q47723984-C581893E-D491-49D4-9C3C-B42ED557D075Q48213165-E4BFBD04-B702-4E14-9806-56C8E69C42FAQ48598107-4911CB2D-774C-4AEF-A7DF-59C11AB02CB1Q48601994-8103C78A-3040-42E2-BAC1-32A450553060Q51150811-51907CAB-DC91-4934-A5C5-39D3FA960462
P2860
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
American Society of Clinical O ...... st cancer: status report 2002.
@ast
American Society of Clinical O ...... st cancer: status report 2002.
@en
American Society of Clinical O ...... st cancer: status report 2002.
@nl
type
label
American Society of Clinical O ...... st cancer: status report 2002.
@ast
American Society of Clinical O ...... st cancer: status report 2002.
@en
American Society of Clinical O ...... st cancer: status report 2002.
@nl
prefLabel
American Society of Clinical O ...... st cancer: status report 2002.
@ast
American Society of Clinical O ...... st cancer: status report 2002.
@en
American Society of Clinical O ...... st cancer: status report 2002.
@nl
P2093
P356
P1476
American Society of Clinical O ...... st cancer: status report 2002.
@en
P2093
Amy S Langer
Clifford Hudis
Eleftherios P Mamounas
Eric P Winer
George P Browman
Harold J Burstein
James N Ingle
Judy Perotti
Julie Gralow
Kathleen I Pritchard
P304
P356
10.1200/JCO.2002.06.020
P407
P577
2002-08-01T00:00:00Z